Effect of Injectable Platelet-rich Fibrin on the En Masse Retraction of Maxillary Anterior Teeth

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-12-01

Study Completion Date

2023-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to investigate the effect of local injection of injectable platelet rich fibrin (i-PRF) on the rate of orthodontic en masse retraction of anterior teeth clinically and to report any associated pain as well.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Multiple Injections of (PRF) on The Rate of Canine Retraction

NCT05766618

Platelet-Rich Fibrin Acceleration Orthodontics

UNKNOWN PHASE3

The Effect of Platelet-rich Fibrin and Vitamin Dꝫ Injections on Canine Retraction

NCT06071455

Acceleration of Tooth Movement

UNKNOWN NA

Efficacy of Injectable Platelet Rich Fibrin (i-PRF) in Enhancing Bone Quality

NCT03399760

Malocclusion, Angle Class II, Division 1

COMPLETED NA

Assesment of Two Different Modalities of Maxillary Canine Retraction Assisted With Injectable Platelet Rich Fibrin

NCT05429437

Effect of Platelet Rich Fibrin Tooth Movement

UNKNOWN PHASE1

Comparative Evaluation of the Regenerative Capacity of Two Platelet Concentrates

NCT03698188

Necrotic Pulp

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Trial will be carried on 2 groups, each involve 13 participants with a total of 26 participants.

1. Subject examination to ensure he/she meets the eligibility criteria of the research.
2. Leveling and alignment using fixed orthodontic appliance.
3. Upper first premolars extraction as a part of the orthodontic treatment planning.
4. With the starting of en masse retraction, injection of the (i-prf) obtained from venous sample palatally and distally to the anterior teeth in the intervention group, and sham injection in the control group. The injection in both groups will be done just before retraction, 21 and 42 days after beginning of retraction Rate of en masse retraction will be calculated for patients in both groups at the monthly basis for for months after starting en masse retraction, data will be analyzed statistically.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Platelet-rich Fibrin

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

interventional group will receive injectable platelet rich fibrin intraligamentally distal to the right and left canines, and palatal to the upper 4 incisors, in three time points with 21 days interval, control group will receive sham injection instead.

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Data assessment will be blinded as an assessor not participating in the study will be responsible for measuring the rate of en masse retraction, as the patient name could be hidden during data analysis. The models will be coded with numbers assigned to the participants, and will be sent to an assessor not participating in the research.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

intervention group

Intervention group subjects will receive injectable platelet rich fibrin (i-prf) . The (i-prf) will be injected in the periodontal ligament of maxillary anterior teeth during en masse retraction.The injection sites will be the sites of bone compression to target the surfaces of the bone where osteoclastogenesis and bone resorption occurs during en masse retraction.

Considering that the obtained (i-prf) after centrifuging would be 4 ml, 1 ml will be injected intraligamentally distal to the right and left canines, and 0.5 ml will be injected intraligamentally palatal to each incisor. The study group will receive i-PRF intraligamentally in the periodontal ligament space of the maxillary six anterior teeth three times as follow, just before anterior teeth retraction, and after 21 days of the retraction, and after 42 days of the retraction. Before each time of injection, an anesthetic solution will be administered for pain control.

Group Type EXPERIMENTAL

injectable platelet rich fibrin(i-prf)

Intervention Type BIOLOGICAL

I-prf is a second-generation PRP where autologous platelets and leukocytes are present in a complex fibrin matrix and can be obtained from blood using low-speed centrifugation without adding anticoagulants.

control group

Subjects in the control group will only receive sham (placebo) injection three successive times with and interval of 21days between each injection, similar to the timepoints of (i-prf) injection in the intervention group. Also the sites of injection will be similar to the sites of injection of the intervention group; 1 ml of the placebo agent will be injected intraligamentally distal to the right and left canines, and 0.5 ml will be injected intraligamentally palatal to each incisor. An anesthetic solution will be administered for pain control before the administration of the sham injections.

Group Type SHAM_COMPARATOR

Sham Injection

Intervention Type DRUG

Sham injection as a placebo injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

injectable platelet rich fibrin(i-prf)

I-prf is a second-generation PRP where autologous platelets and leukocytes are present in a complex fibrin matrix and can be obtained from blood using low-speed centrifugation without adding anticoagulants.

Intervention Type BIOLOGICAL

Sham Injection

Sham injection as a placebo injection

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Orthodontic patients with and age range (16 - 30) years.
2. Protruded upper anterior teeth requiring extraction of first premolars and anterior teeth retraction; Angle class I mal-occlusion with bi-alveolar dental protrusions or class II division 1.
3. Patients with full permanent dentition (with the exception of third molars).
4. Healthy dental and periodontal condition with good oral hygiene

Exclusion Criteria

1. Patients with extensive restorations on the anterior teeth.
2. Subjects taking medication affecting inflammatory process of the orthodontic tissue reaction.
3. History of previous orthodontic treatment or trauma to the anterior teeth.
4. Syndromic patients and patients with systemic diseases.
5. Poor oral hygiene or periodontal diseases.

Minimum Eligible Age

16 Years

Maximum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes